Received Aug 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 1 | — | — |
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 2 | — | — |
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 3 | Z005852 | — |
No additional AE/No PQC.; HCP calling to report a 3rd dose of VAQTA administered today (08/06/2025) to a patient who has already received their two doses in the past. The two doses were administered on 08/04/2022 and 02/03/2023, respectively. Confirmed patient is not symptoma; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 04-AUG-2022, the patient was vaccinated with first dose of Hepatitis A Vaccine, Inactivated (VAQTA) (dose, route of administration, anatomical location, lot number and expiration date were not reported). On 03-FEB-2023, the patient was vaccinated with second dose of Hepatitis A Vaccine, Inactivated (VAQTA) (dose, route of administration, anatomical location, lot number and expiration date were not reported) and on 06-AUG-2025, the patient received a third dose of Hepatitis A Vaccine, Inactivated (valid lot number Z005852, expiration date: 15-OCT-2026) for prophylaxis (extra dose administered). Confirmed patient was not symptomatic. No other information available at that time. No additional adverse event (AE).